| Property | Value |
|---|
|
?:abstract
|
-
COVID-19 is an emerging viral infection of zoonotic origin that is closely related to the severe acute respiratory syndrome coronavirus (SARS-CoV) that caused an outbreak in 2003. Therefore, scientists named the new virus SARS-CoV-2. On March 11, 2020, The World Health Organization (WHO) recognized COVID-19 as a global pandemic. At present, three vaccines have been approved or are being considered for approval by national regulatory agencies to immunize against COVID-19. However, the vaccines do not yet remain widely available and no specific treatment against the virus is available. The pathogenesis and proliferation pathways of SARS-CoV-2 are still not well known. Thus, in this article, the saponin glycyrrhizin is discussed as a new potential therapeutic agent of natural origin (licorice root, Glycyrrhizaglabra) for the potential treatment of COVID-19 infections.
|
|
?:creator
|
|
|
?:doi
|
-
10.2174/1389557521666210210160237
|
|
?:doi
|
|
|
?:journal
|
-
Mini_reviews_in_medicinal_chemistry
|
|
?:license
|
|
|
?:pmid
|
|
|
?:pmid
|
|
|
?:publication_isRelatedTo_Disease
|
|
|
?:source
|
|
|
?:title
|
-
Glycyrrhizin as a Potential Treatment for the Novel Coronavirus (COVID-19).
|
|
?:type
|
|
|
?:year
|
|
![[This page as RDF]](https://research.tib.eu/covid-19/static/rdf-icon.gif){kind=icon}